Filters
Older adults who have undergone percutaneous coronary intervention (PCI) may do well with a shortened dual antiplatelet therapy (DAPT) duration, which has been shown to reduce the risk of bleeding without increasing the risk of adverse clinical events in a network meta-analysis.
New drug applications approved by US FDA as of 16-31 March 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Reducing alcohol consumption helps lower the risk of future adverse cardiovascular events, especially angina and ischaemic stroke, among people who drink heavily, according to a study.
Researchers from a joint team at the University of Hong Kong (HKU) and Chinese Academy of Sciences have developed a novel neutralizing monoclonal antibody (mAb; 6H2) that targets circulating adipocyte fatty acid–binding protein (A-FABP), offering potential in alleviating cerebral ischaemic injury.
Renal denervation yields substantial reductions in ambulatory systolic blood pressure for up to 36 years in randomized controlled trials and up to 10 years in observational cohort studies without compromising renal function, according to the results of a systematic review and meta-analysis.
Very elderly patients with nonvalvular atrial fibrillation fare well with either edoxaban or apixaban in terms of stroke prevention, although those on edoxaban may have higher bleeding risk, according to a study.
Adding colchicine to anakinra appears to work well in reducing the incidence of recurrent pericarditis, according to a study.
In the treatment of patients with type 2 diabetes and peripheral artery disease (PAD), a 6-month course of liraglutide results in increased peripheral perfusion, according to the results of an open-label study.
Eating “planet-friendly” foods may result in better cardiovascular (CV) health in adolescents, according to a study involving European participants.
In patients with new-onset postoperative atrial fibrillation (POAF) following coronary artery bypass grafting (CABG), early AF recurrence is common but not associated with death, according to a study.
